Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Global Blood nets $96.3mm through follow-on offering

Executive Summary

Global Blood Therapeutics Inc. (lead candidate is for sickle cell disease) netted $96.3mm through the public offering of 2.6mm common shares at $36.80. Proceeds will support late-stage trials of lead candidate voxelotor (GBT440) for sickle cell disease in adults and children.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register